MORINAGA-MILK-INDUSTRY
30.5.2024 20:01:28 CEST | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, has announced a groundbreaking discovery in the fundamental research of Human-Residential Bifidobacteria (HRB). Through a joint collaboration with Kyoto University, the research has discovered that a specific type of bifidobacteria living in humans, also known as HRB, has the ability to convert precursors of a potentially harmful component into a beneficial metabolite. The research team has uncovered a previously unknown metabolic pathway utilized by the HRB species, converting indole, a potentially harmful compound, into the immunomodulatory metabolite indole-3-lactic acid (ILA). The findings, published in the prestigious journal "Gut Microbes" on May 5, 2024, underscore the unique capabilities of HRB as superior probiotics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530532346/en/
Human-Residential Bifidobacteria (HRB) strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63, significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1). Subsequently, the research demonstrated that HRB strains can convert the potentially harmful indole into tryptophan (Trp) and beneficial indole-3-lactate (ILA) (Figure 2). The study also identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3), highlighting the sophisticated mechanisms by which specific HRB strains contribute to gut health. (Graphic: Business Wire)
Research Background
The research focused on indole, a compound produced by certain intestinal bacteria, which is metabolized in the liver and converted into indoxyl sulfate, a typical urinary toxin. When renal function is impaired, indole and indoxyl sulfate can accumulate in the blood, leading to potential health issues, such as the progression of kidney dysfunction. The formation of indole, which is derived from tryptophan, an essential amino acid for humans, may lead to harmful impacts that are inevitable and pose significant health concerns. In collaboration with Kyoto University, Morinaga Milk’s new research aimed to investigate whether HRB strains could reduce the concentration of indole and transform it into a beneficial metabolite, and understand the underlying mechanism.
Groundbreaking Findings Backed HRB Superiority
- Reduction of Indole Concentration: The study revealed that a specific type of bifidobacteria living in humans, including Morinaga Milk’s HRB strains such as Bifidobacterium longum BB536, B. breve M-16V, B. breve MCC1274, and B. infantis M-63 significantly reduced the concentration of indole produced by Escherichia coli, a known indole producer (Figure 1).
- Conversion of Indole into Tryptophan (Trp) and Indole-3-Lactate (ILA): The research demonstrated that selected bifidobacterial strains, including Morinaga Milk’s HRB strains, can convert indole into tryptophan (Trp) and indole-3-lactate (ILA) (Figure 2). While tryptophan is a necessary amino acid, ILA has been identified as an immunomodulatory compound that supports intestinal and systemic immune health. This discovery marks a significant step forward in understanding how beneficial gut bacteria can transform harmful substances into compounds that promote health.
- Metabolic Pathway Elucidation: The study identified a new microbial metabolic pathway involving tryptophan synthase β subunit (TrpB) and aromatic lactate dehydrogenase (ALDH) in the conversion process (Figure 3). The researchers confirmed that selected bifidobacterial strains, including Morinaga Milk’s HRB strains can efficiently transform exogenous indole into ILA and Trp. This elucidation of the metabolic pathway provides a detailed understanding of the biochemical processes involved, highlighting the sophisticated mechanisms by which bifidobacteria contribute to gut health.
- Exclusive Presence in HRB: An extensive genome database search of 11,943 bacterial strains revealed that the co-occurrence of trpB and aldh genes is exclusive to HRB species. This specificity underlines the unique probiotic potential of these bifidobacteria in human health applications. The genomic analysis underscores the distinctiveness of HRB, positioning them as uniquely capable of performing these beneficial transformations.
Implications for Health
These findings highlight the potential of HRB strains, such as those commercialized by Morinaga Milk, in mitigating the harmful effects of indole by converting it into beneficial ILA. This novel function of bifidobacteria highlights their beneficial effects on human, where indole and its metabolites pose potential adverse health effects for individuals with high risks of chronic kidney disease. Moreover, the conversion of indole into tryptophan and ILA also suggests broader implications for overall gut health. Tryptophan is essential for protein synthesis and serves as a precursor for serotonin, a neurotransmitter that plays a critical role in mood regulation and overall well-being. The production of ILA, with its immunomodulatory properties, further supports the immune system, suggesting the additional health potentials of HRB as probiotics. These findings provide valuable insights into the reasons why HRB species thrive in the human intestinal tract and maintain a symbiotic relationship with the human host.
Continued Commitment to HRB Research
Morinaga Milk Industry remains dedicated to advancing our understanding of HRB and their health benefits. This discovery is a testament to our commitment to innovative research and developing high-quality, scientifically-backed probiotic products that contribute to human health and well-being. Our ongoing research endeavors aim to uncover even more ways in which HRB strains can benefit human health, reinforcing our position as a leader in the field of probiotics.
Embrace the Future: Aim Higher!
Under the Morinaga Milk Group's 10-Year Vision, the company aims to achieve an overseas sales ratio of 15% or more by the fiscal year ending March 2029. The company will continue its effort in developing and providing effective HRB probiotics with a higher level of safety and quality, aiming to strengthen its probiotic sales in the global marketplace to help achieve the goal.
About Morinaga Milk Industry
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530532346/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 13:00:00 CEST | Press release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
Infobip Launches PitchMate — An AI Fan Companion for Global Football2.7.2026 12:00:00 CEST | Press release
Two AI agents. Two global sports. One platform redefining what it means to be a fan. Global AI-first cloud communications platform Infobip launched PitchMate, a new AI-powered conversational agent that brings football fans closer to the action of the world’s biggest football tournament. Purpose-built for the global football audience, PitchMate joins the TGR Haas F1 Team RaceMate — Infobip’s AI fan engagement solution for the TGR Haas F1 Team — in demonstrating how conversational AI is transforming fan engagement across sports worldwide. RaceMate, launched last April for this year’s motorsport season, is an AI agent on WhatsApp and Apple Messages for Business that puts TGR Haas F1 Team fans at the center of the action. It delivers real-time race data, personalized content, team radio highlights, trivia, and native multilingual support, turning passive viewers into active participants through natural, human-like conversations across every race weekend. Since its launch, RaceMate has reac
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies2.7.2026 11:00:00 CEST | Press release
Acquisition brings together Besins Healthcare's hormonal health leadership and UniD's expertise in the development and manufacturing of advanced polymer based pharmaceutical formulations.1UniD Manufacturing to become Besins Healthcare PharmTech, serving as a strategic innovation hub within the company while continuing to serve its clients. Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/ Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies This acquisition brings together two highly compatible areas. Besins Healthcare bri
ROYC Selected by Slättö as Structuring and Platform Solution for Luxembourg Feeder Fund2.7.2026 10:45:00 CEST | Press release
ROYC, a leading global structuring and platform provider, today announced that Slättö, a Nordic private markets real estate firm, has selected ROYC to establish and manage a Luxembourg-domiciled feeder fund designed to efficiently aggregate individual subscriptions from professional investors. The Luxembourg-domiciled vehicle will be fully structured and administered on ROYC’s proprietary platform, delivering investors a seamless digital experience with real-time portfolio access, automated reporting, and efficient global distribution. ROYC streamlines onboarding and governance, standardizes legal documentation, and broadens access to capital. “Private markets are undergoing a structural shift as global banks and wealth platforms increasingly seek efficient access to high-quality private equity strategies. By combining our deep structuring expertise with ROYC’s digital operating infrastructure, we enable leading managers like Slättö to launch investor-ready vehicles rapidly while deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
